These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

322 related articles for article (PubMed ID: 23925000)

  • 21. Improved safety of a replication-competent poxvirus-based HIV vaccine with the introduction of the HSV-TK/GCV suicide gene system.
    Zhang Q; Liu Z; Hou J; Wang S; Liu C; Wei M; Liu Y; Shao Y
    Vaccine; 2016 Jun; 34(30):3447-53. PubMed ID: 27195760
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Heterologous prime-boost-boost immunisation of Chinese cynomolgus macaques using DNA and recombinant poxvirus vectors expressing HIV-1 virus-like particles.
    Bridge SH; Sharpe SA; Dennis MJ; Dowall SD; Getty B; Anson DS; Skinner MA; Stewart JP; Blanchard TJ
    Virol J; 2011 Sep; 8():429. PubMed ID: 21899739
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immunogenicity of seven new recombinant yellow fever viruses 17D expressing fragments of SIVmac239 Gag, Nef, and Vif in Indian rhesus macaques.
    Martins MA; Bonaldo MC; Rudersdorf RA; Piaskowski SM; Rakasz EG; Weisgrau KL; Furlott JR; Eernisse CM; Veloso de Santana MG; Hidalgo B; Friedrich TC; Chiuchiolo MJ; Parks CL; Wilson NA; Allison DB; Galler R; Watkins DI
    PLoS One; 2013; 8(1):e54434. PubMed ID: 23336000
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Highly effective control of an AIDS virus challenge in macaques by using vesicular stomatitis virus and modified vaccinia virus Ankara vaccine vectors in a single-boost protocol.
    Ramsburg E; Rose NF; Marx PA; Mefford M; Nixon DF; Moretto WJ; Montefiori D; Earl P; Moss B; Rose JK
    J Virol; 2004 Apr; 78(8):3930-40. PubMed ID: 15047809
    [TBL] [Abstract][Full Text] [Related]  

  • 25. HIV/AIDS Vaccine Candidates Based on Replication-Competent Recombinant Poxvirus NYVAC-C-KC Expressing Trimeric gp140 and Gag-Derived Virus-Like Particles or Lacking the Viral Molecule B19 That Inhibits Type I Interferon Activate Relevant HIV-1-Specific B and T Cell Immune Functions in Nonhuman Primates.
    García-Arriaza J; Perdiguero B; Heeney JL; Seaman MS; Montefiori DC; Yates NL; Tomaras GD; Ferrari G; Foulds KE; Roederer M; Self SG; Borate B; Gottardo R; Phogat S; Tartaglia J; Barnett SW; Burke B; Cristillo AD; Weiss DE; Lee C; Kibler KV; Jacobs BL; Wagner R; Ding S; Pantaleo G; Esteban M
    J Virol; 2017 May; 91(9):. PubMed ID: 28179536
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Novel vaccine delivery systems: solutions to HIV vaccine dilemmas?
    Sutter G; Haas J
    AIDS; 2001; 15 Suppl 5():S139-45. PubMed ID: 11816162
    [No Abstract]   [Full Text] [Related]  

  • 27. Oral Immunization with Recombinant Vaccinia Virus Prime and Intramuscular Protein Boost Provides Protection against Intrarectal Simian-Human Immunodeficiency Virus Challenge in Macaques.
    Thippeshappa R; Tian B; Cleveland B; Guo W; Polacino P; Hu SL
    Clin Vaccine Immunol; 2015 Dec; 23(3):204-12. PubMed ID: 26718849
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Nonreplicating vectors in HIV vaccines.
    Johnson JA; Barouch DH; Baden LR
    Curr Opin HIV AIDS; 2013 Sep; 8(5):412-20. PubMed ID: 23925001
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Replication-defective HIV as a vaccine candidate.
    Tung FY; Rinaldo CR; Montelaro RC
    AIDS Res Hum Retroviruses; 1998 Sep; 14(14):1247-52. PubMed ID: 9764908
    [TBL] [Abstract][Full Text] [Related]  

  • 30. First-in-Human Randomized, Controlled Trial of Mosaic HIV-1 Immunogens Delivered via a Modified Vaccinia Ankara Vector.
    Baden LR; Walsh SR; Seaman MS; Cohen YZ; Johnson JA; Licona JH; Filter RD; Kleinjan JA; Gothing JA; Jennings J; Peter L; Nkolola J; Abbink P; Borducchi EN; Kirilova M; Stephenson KE; Pegu P; Eller MA; Trinh HV; Rao M; Ake JA; Sarnecki M; Nijs S; Callewaert K; Schuitemaker H; Hendriks J; Pau MG; Tomaka F; Korber BT; Alter G; Dolin R; Earl PL; Moss B; Michael NL; Robb ML; Barouch DH;
    J Infect Dis; 2018 Jul; 218(4):633-644. PubMed ID: 29669026
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Replicating viral vectors as HIV vaccines: summary report from the IAVI-sponsored satellite symposium at the AIDS vaccine 2009 conference.
    Excler JL; Parks CL; Ackland J; Rees H; Gust ID; Koff WC
    Biologicals; 2010 Jul; 38(4):511-21. PubMed ID: 20537552
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Live recombinant vectors for AIDS vaccine development.
    Voltan R; Robert-Guroff M
    Curr Mol Med; 2003 May; 3(3):273-84. PubMed ID: 12699363
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Stable and Highly Immunogenic MicroRNA-Targeted Single-Dose Live Attenuated Vaccine Candidate against Tick-Borne Encephalitis Constructed Using Genetic Backbone of Langat Virus.
    Tsetsarkin KA; Maximova OA; Liu G; Kenney H; Teterina NL; Pletnev AG
    mBio; 2019 Apr; 10(2):. PubMed ID: 31015334
    [TBL] [Abstract][Full Text] [Related]  

  • 34. CD8 T Cells Show Protection against Highly Pathogenic Simian Immunodeficiency Virus (SIV) after Vaccination with SIV Gene-Expressing BCG Prime and Vaccinia Virus/Sendai Virus Vector Boosts.
    Kato S; Shida H; Okamura T; Zhang X; Miura T; Mukai T; Inoue M; Shu T; Naruse TK; Kimura A; Yasutomi Y; Matsuo K
    J Virol; 2021 Jan; 95(4):. PubMed ID: 33087465
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunogenicity of viral vector, prime-boost SIV vaccine regimens in infant rhesus macaques: attenuated vesicular stomatitis virus (VSV) and modified vaccinia Ankara (MVA) recombinant SIV vaccines compared to live-attenuated SIV.
    Van Rompay KK; Abel K; Earl P; Kozlowski PA; Easlick J; Moore J; Buonocore-Buzzelli L; Schmidt KA; Wilson RL; Simon I; Moss B; Rose N; Rose J; Marthas ML
    Vaccine; 2010 Feb; 28(6):1481-92. PubMed ID: 19995539
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Progress in the development of an HIV-1 vaccine.
    Letvin NL
    Science; 1998 Jun; 280(5371):1875-80. PubMed ID: 9632379
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cross-protection against mucosal simian immunodeficiency virus (SIVsm) challenge in human immunodeficiency virus type 2-vaccinated cynomolgus monkeys.
    Walther-Jallow L; Nilsson C; Söderlund J; Ten Haaft P; Mäkitalo B; Biberfeld P; Böttiger P; Heeney J; Biberfeld G; Thorstensson R
    J Gen Virol; 2001 Jul; 82(Pt 7):1601-1612. PubMed ID: 11413371
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Safety and immunogenicity in neonatal mice of a hyperattenuated Listeria vaccine directed against human immunodeficiency virus.
    Rayevskaya M; Kushnir N; Frankel FR
    J Virol; 2002 Jan; 76(2):918-22. PubMed ID: 11752181
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The novel capripoxvirus vector lumpy skin disease virus efficiently boosts modified vaccinia Ankara human immunodeficiency virus responses in rhesus macaques.
    Burgers WA; Ginbot Z; Shen YJ; Chege GK; Soares AP; Müller TL; Bunjun R; Kiravu A; Munyanduki H; Douglass N; Williamson AL
    J Gen Virol; 2014 Oct; 95(Pt 10):2267-2272. PubMed ID: 24866849
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Expression of complete SIV p27 Gag and HIV gp120 engineered outer domains targeted by broadly neutralizing antibodies in live rubella vectors.
    Virnik K; Nesti E; Dail C; Hockenbury M; Ni Y; Felber BK; Schief WR; Berkower I
    Vaccine; 2017 May; 35(24):3272-3278. PubMed ID: 28483193
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.